Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database.

Archive ouverte

Nguyễn, Thủy | Maria, Alexandre Thibault Jacques | Ladhari, Chayma | Palassin, Pascale | Quantin, Xavier | Lesage, Candice | Taïeb, Guillaume | Ayrignac, Xavier | Rullier, Patricia | Hillaire-Buys, Dominique | Lambotte, Olivier | Guilpain, Philippe | Faillie, Jean-Luc

Edité par CCSD ; BMJ Publishing Group -

International audience. As shown by Kostine et al,1 and recently underlined by Ceccarelli et al,2 rheumatic inflammatory disorders induced by anticancer therapy are becoming a major concern for rheumatologists at the era of immune checkpoint inhibitors (ICIs). Beyond inflammatory arthritis, which may concern 10%–20% of patients, myositis represents a rare (<1%) but potentially life-threatening event. We thus aimed at investigating the risk of ICI-related myositis in real-life setting using VigiBase, the WHO’s pharmacovigilance database.

Suggestions

Du même auteur

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series

Archive ouverte | Coustal, Cyrille | CCSD

International audience. Background : Immune checkpoint inhibitors (ICI) have transformed cancer treatment over the last decade. Alongside this therapeutic improvement, a new variety of side effects has emerged, call...

Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study

Archive ouverte | Palassin, Pascale | CCSD

International audience. Immune checkpoint inhibitors (ICI) restore immune response against cancer cells that can lead to immune-related adverse effects. While cardiovascular immune-related adverse effects are known ...

Immune checkpoint inhibitors induced liver injury: an observational study

Archive ouverte | Hountondji, Lina | CCSD

International audience. Introduction: Liver toxicity associated with immune checkpoint inhibitors (ICI), such as PD-1, PD-L1 and CTLA-4 inhibitors, is frequent. International guidelines recommend pausing immunothera...

Chargement des enrichissements...